These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25294123)

  • 1. The development of potential antibody-based therapies for myeloma.
    Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
    Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True.
    D'Agostino M; Innorcia S; Boccadoro M; Bringhen S
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33139668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapy With Immunoconjugates for Multiple Myeloma.
    Bruins WSC; Zweegman S; Mutis T; van de Donk NWCJ
    Front Immunol; 2020; 11():1155. PubMed ID: 32636838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.
    Chatterjee M; Chakraborty T; Tassone P
    Eur J Cancer; 2006 Jul; 42(11):1640-52. PubMed ID: 16797969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-body building: The exercise of advancing immune based myeloma therapies.
    Richter J; Thibaud S
    Blood Rev; 2021 Jul; 48():100789. PubMed ID: 33384171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
    Eckhert E; Hewitt R; Liedtke M
    Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
    Yu B; Liu D
    J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
    Sherbenou DW; Su Y; Behrens CR; Aftab BT; Perez de Acha O; Murnane M; Bearrows SC; Hann BC; Wolf JL; Martin TG; Liu B
    Clin Cancer Res; 2020 Nov; 26(22):6028-6038. PubMed ID: 32917735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecifics, trispecifics, and other novel immune treatments in myeloma.
    Lancman G; Richter J; Chari A
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):264-271. PubMed ID: 33275733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
    Hutchinson AT; Jones DR; Raison RL
    Mol Immunol; 2015 Oct; 67(2 Pt A):89-94. PubMed ID: 25964097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
    Wudhikarn K; Wills B; Lesokhin AM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-maytansinoid conjugates for the treatment of myeloma.
    Lutz RJ; Whiteman KR
    MAbs; 2009; 1(6):548-51. PubMed ID: 20068397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.